Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
FOLE was recently approved for use in
2022-08-19

FOLE was recently approved for use in PN-dependent patients in the United States. However, potential adverse effects of FOLE, including bleeding risk, and effects on the immune system [8], [39], render its use in certain patient populations controversial. Identification of key downstream modulators
-
Emodepside After initial validation of the ability of Ad Cre
2022-08-18

After initial validation of the ability of Ad5-Cre virus to express Cre recombinase protein in glial cells in vitro and in vivo, we employed this virus to induce site-specific deletion of our target GlyT1 in the thalamus, through injection of the cKO GlyT1 mice. This transgenic line was constructed
-
br Acknowledgments This work was financially supported by th
2022-08-18

Acknowledgments This work was financially supported by the National Natural Science Foundation of China (No. 81703451) and the China Postdoctoral Science Foundation Grant (No. 2017M611269). Introduction According to the International League Against Epilepsy (ILAE), epilepsy is generally defin
-
It is notable that pharmacological or genetic
2022-08-18

It is notable that pharmacological or genetic inhibition of GCGR signaling results in the engagement of a number of compensatory mechanisms that potentially impact glucose control. These include alpha-cell hyperplasia [2], [11], [12], [13] and increased beta-cell proliferation under low insulin cond
-
br Genetic manipulation variation of the ghrelin system and
2022-08-18

Genetic manipulation/variation of the ghrelin system and alcohol-related outcomes Genetic manipulation of the ghrelin system (either the peptide or the receptor gene) via knockout rodent models has provided further insight into the role of this system in alcohol seeking and consummatory behaviors
-
Together our data are consistent with the idea that
2022-08-18

Together, our data are consistent with the idea that the antidepressant-like effect of a low dose of galanin administration in the DRN would be mediated by the activation of local GAL2. To support this hypothesis, we set an additional experiment to evaluate whether the antidepressant-like effect of
-
In summary metagenome sequencing of paddy soil was performed
2022-08-18

In summary, metagenome sequencing of paddy soil was performed with 55.68 Gb sequences, and subsequent data mining was performed for functional profiles and metabolic pathways. Several GH family proteins, such as amylases, cellulases, xylanases, and galactosidases, were explored in the paddy soil met
-
We reviewed the results of
2022-08-18

We reviewed the results of comprehensive genomic profiling (CGP) in 26,054 cases of NSCLC and examined the frequency and clinical characteristics of patients whose tumors harbor FGFR fusions. To our knowledge, this is the most in-depth evaluation of FGFR fusions exclusively in NSCLC. Here we will de
-
Ning et al showed that LPC appeared
2022-08-18

Ning et al. showed that LPC 18:1 appeared to increase insulin release through both GPR119-dependent and -independent mechanisms (Ning et al., 2008). In our study, we have shown that not only GPR119 but also GPR40 and GPR55 participate in LPC-stimulated insulin secretion (Fig. 4, Fig. 5) and target p
-
Introduction Thrombotic disorders including ischemic heart
2022-08-18

Introduction Thrombotic disorders including ischemic heart disease, deep venous thrombosis, and ischemic stroke represent one of the most common causes of death in the world [1]. All these conditions relate to states accompanied by a shift of hemostasis balance into a coagulation side because of va
-
br STAR Methods br Acknowledgments The authors would like to
2022-08-17

STAR★Methods Acknowledgments The authors would like to acknowledge Genentech DNA Sequencing, Biologics Resource, Oligo, FACS, and Bioinformatics groups for their help with the project. Our thanks to Craig Cumming and Sophia Maund for facilitating our access to large-scale mutation data. We als
-
Trigonelline These inhibitors possess a cap group build from
2022-08-17

These inhibitors possess a cap group build from cyclization of several amino-acid or non-amino-acid residues, four or more, with one residue bearing an alkyl arm terminated by ZBGs of various types: thiols, ketones or epoxides. In the case of romidepsin 30 (Fig. 7), the thiol group is initially in a
-
The following are the supplementary data related to
2022-08-17

The following are the supplementary data related to this article. Transparency Document Acknowledgements Introduction Nitric oxide (NO) is an important signaling molecule mediating several physiological functions including vasodilation, platelet anti-aggregation, inhibition of interstitial
-
br Acknowledgements br Introduction The study methods
2022-08-17

Acknowledgements Introduction The study methods consisted of the review of articles included in the Pubmed and Medline databases and in the clinicaltrials.gov clinical trials register between 2013 and 2016, and of the preliminary results of therapies presented at international trichology confe
-
br Acknowledgements We thank the support of the National
2022-08-17

Acknowledgements We thank the support of the National Natural Science Foundation of China (NSFC) project 81501342 and support from the Disciplinary Group of Oncology and Immunology program of Xinxiang Medical University. Introduction First described as a new clinical entity in 1981, the Acqui
16744 records 421/1117 page Previous Next First page 上5页 421422423424425 下5页 Last page